QUOTED. Toon Overbeeke.
Dutch-based Vitestro will soon enter pivotal trials with its autonomous blood-sampling device, which it hopes to market in 2024, pending regulatory approval. See what Vitestro’s CEO, Toon Overbeeke, said about one of the challenges in the ongoing development of the phlebotomist robot here.
“You really need submillimeter precision in order to make sure that the needle is really in the middle of the vein.” – Toon Overbeeke, CEO, Vitestro
Click here for a free trial of Medtech Insight